News
Kamada says final analysis confirms safety, efficacy of IV product
NESS ZIONA, Israel—Kamada, a biopharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced today that it has completed the final analysis of its US Phase III trial with intravenous Alpha-1 Antitrypsin (AAT), for hereditary AAT deficiency.
The analysis confirmed preliminary results announced in April. The company has now officially completed the clinical stage of this product’s development, high safety profile sided to meeting the primary endpoint were determined.
Kamada plans to file a Biologic License Application with the US Food and Drug Administration in 2009. Information about the study will be presented at an upcoming major medical conference.
